Focus: Drugmakers go under the skin, skirting early US Medicare price negotiations

 Injectable versions of some widely-used cancer drugs including Johnson & Johnson's (JNJ.N) blockbuster multiple myeloma treatment Darzalex are likely to be excluded from new U.S. government price negotiations for years, drugmakers told Reuters, protecting billions in revenue.